Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
A phase 2 trial of Cetuximab in head and neck squamous cell carcinoma, run by Shanghai Institute Of Biological Products, now recruiting.
Overview
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06194656 by Shanghai Institute Of Biological Products, with 81 participants planned, started 2024-09-27 and due to reach its primary completion in 2026-07-30. Interventions recorded: HER3 Monoclonal antibodies-Dose A, HER3 Monoclonal antibodies-Dose B, HER3 Monoclonal antibodies-Dose C, HER3 Monoclonal antibodies-Dose D, Placebo. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Setting
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SIBP-03 Injection Combined With Cetuximab in Patients With Recurrent/Metastatic Advanced Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma)
Phase
Phase 2
Sponsor
Shanghai Institute Of Biological Products
Registry
Enrolled
81
Similar pages
not linked directly; found by shared links- TreatmentNimotuzumab
- TrialStudy for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
- TrialA Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
- TrialA Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
- TrialAK129 Combination Therapy for Advanced Solid Tumors
- InstitutionUPMC Hillman Cancer Center
- CompanyMerck KGaA (EMD Serono)